Catalyst Final Award
Principal Investigators: Charles Langelier, MD, PhD – Emily Lydon, MD
Team Members: Carolyn Calfee, MD, MAS – Hoang Van Pham, PhD – Rithwik Narendra, BS
Intern: Angela Li, PhD candidate
Project Name: AirCode – Rapid host biomarkers for diagnosis and prognosis of severe respiratory infections
"Complementary host biomarkers measured rapidly at the true site of infection."
Catalyst Final Award
Principal Investigator: Maria Wei, MD, PhD
Team Members: Vincent Wu, MBA – Rodrigo Torres, PhD
Interns: Audrey Su, MS candidate – Amy Kumar, MD candidate
Project Name: InformaDerm, Inc – Non-invasive multi-cancer AI molecular classifier for skin cancer
"InformaDerm Multi-classifier provides molecular detection of skin lesions made accessible, accurate, easy, and painless."
Catalyst Final Award
Principal Investigator: Terumi Kohwi-Shigematsu, PhD
Team Members: Yoshinori Kohwi, PhD
Interns: Zerong Ma, PhD – Aria Oweissi, MEng-MTM candidate
Project Name: iMET – Gene expression-based tool to assess the metastatic potential of triple-negative breast cancer
"We developed a gene panel to evaluate the metastatic risk of TNBC to invade, disseminate, and colonize distant organs."
Weill Institute-Catalyst Final Award
Principal Investigators: Joseph DeRisi, PhD – Michael Wilson, MD – Caroline Vissers, PhD
Interns: Sharlene Shirali, MD candidate – Amando III Lumanbang, RN
Project Name: Immunectra – Commercialization of an immune biomarker blood test for the diagnosis of multiple sclerosis during the prodromal phase
"Immunectra has identified the first-ever multiple sclerosis-specific biomarkers and optimized them into a high-throughput blood test that can diagnose multiple sclerosis earlier than any other method, directly addressing the massive unmet needs in early and accurate diagnosis of MS."
Weill Institute-Catalyst Final Award
Principal Investigators: Brooke Braman, MD – David Raleigh, MD, PhD
Interns: Evan Chau – Ali Tejani, MD
Project Name: RespondRT – Validation of a targeted gene expression biomarker for overall survival after re-irradiation in recurrent glioblastoma
"Our biomarker is the first-in-kind molecularly-guided test to identify glioblastomas that benefit from re-irradiation at disease recurrence, helping physicians and patients make data-driven decisions about re-irradiation to maximize outcomes and avoid unnecessary toxicity and healthcare costs."
